Therefore, the objective of this study is to investigate the incidence of treatment-related adverse events (trAEs) of combination EGFR-TKI and ICIs in advanced EGFR-mutant NSCLC patients who have previously received TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.